ADIAL PHARMACEUTICALS, INC. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On September 17, 2026, Adial Pharmaceuticals stockholders approved Amendment No. 8 to the 2017 Equity Incentive Plan (increasing shares from 200,000 to 225,666) and adopted two new plans: the 2026 Equity Incentive Plan (3,078,147 shares plus up to 196,670 returning shares, with 5% annual increases for ten years) and the 2026 Employee Stock Purchase Plan (307,815 shares plus 1% annual increases for ten years). These are standard equity compensation plans with no material counterparty agreements or dollar amounts specified.
Why this rating
Routine equity plan adoption/amendment. At $6.5M market cap, the share dilution is material (aggregate ~3.3M shares), but these are boilerplate administrative filings with no operational business impact or financial transactions.
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.